Parmax Pharma Ltd Share Price

Parmax Pharma
Small Cap | Pharmaceuticals
₹ 34.5 2.7 (8.49%)
Last updated: 15-Oct-2025 , 16:01:47

Parmax Pharma Ltd Live Price Chart

Low: ₹29.9 High: 34.5
Open Your Trading & Demat Account
+91

Parmax Pharma Ltd Technicals

Current Price
₹ 34.5 2.7 (8.49%)
EMASMA
20 Day ₹ 32.524
50 Day ₹ 34.474
100 Day ₹ 36.733
200 Day ₹ 38.447
20 Day ₹ 32.377
50 Day ₹ 34.659
100 Day ₹ 37.428
200 Day ₹ 40.197

Parmax Pharma Ltd Performance

Previous Close ₹ 31.8
High ₹ 34.5
Volume 754
52W Range ₹ 29.9 - ₹ 55.02
Open ₹ 31.8
Low ₹ 29.9
Market Cap 11.9 Cr

Parmax Pharma Ltd Fundamentals

ROCE -12.907
P/E Ratio -4.500
P/B Ratio 0.000
Industry P/E 0.000
Debt to Equity 39.893
ROE 51.393
EPS -7.670
Dividend Yield 0.000
Book Value -7.213
Face Value 10.000

Parmax Pharma Ltd Financials

Particulars Y202503 Y202403 Y202303 Y202203 Y202103
Total Revenue 28.2435355 11.101150359 15.464066258 18.3148362 26.293405
Total Expenses 29.5666773 16.757024561 15.417943165 18.0115662 25.0849653
Profit After Tax -2.0940101 -5.778772746 -0.104068307 0.1415133 0.7544218

Parmax Pharma Ltd Shareholding Pattern

Promoter Holdings 30.804 %
FIIs 0.000 %
DIIs 0.000 %
MutualFund 0.000 %
Retail 63.095 %
Others - 6.101 %

About Parmax Pharma Ltd

History of Parmax Pharma Ltd

Incorporated in Nov.'94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara. The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The Company then discontinued their business activities for few years due to various reasons. Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an inst ...

Similar Stocks

Company 52 Week Market Price P/E Ratio
Gujarat Themis Biosyn Ltd ₹ 208 - ₹ 435 430 105.13
Jubilant Pharmova Ltd ₹ 802 - ₹ 1309.9 1060.4 486.47
Anuh Pharma Ltd ₹ 74.25 - ₹ 122.85 78.83 17.14
Aarti Drugs Ltd ₹ 312 - ₹ 564.05 507.5 26.12
Aarey Drugs & Pharmaceuticals Ltd ₹ 31.35 - ₹ 86.85 83.94 57.1

FAQs on Parmax Pharma Ltd

1. Can I buy Parmax Pharma Ltd from PL Capital? ›

Yes, you can invest in Parmax Pharma Ltd shares directly through PL Capital. Our platform provides a seamless and secure way to buy, hold, and track Parmax Pharma Ltd stock along with other leading companies listed on the NSE and BSE. Simply open a Demat and trading account with PL Capital, and you’ll be able to trade Parmax Pharma Ltd as well as diversify your portfolio across equities, mutual funds, IPOs, and more.

2. Does Parmax Pharma Ltd pay dividends? ›

Parmax Pharma Ltd does not currently pay dividends. Investors in this case primarily benefit from capital appreciation, where the value of the stock may rise over time depending on business growth and market conditions.

3. What is the current share price of Parmax Pharma Ltd ? ›

As of 15-10-2025 the share price for Parmax Pharma Ltd. is 34.5 on the NSE (Note: Prices are dynamic and update frequently during market hours).

4. What is the 52-week high and low of Parmax Pharma Ltd ? ›

The 52-week high and low of Parmax Pharma Ltd share price is ₹ 29.9 - ₹ 55.02 as of 15-10-2025 .
PL Ringside View

Our fireside chat series where industry experts and top management share valuable insights for our clients

Youtube

Mark Mobius on India’s Growth, Global Markets, and Investment Opportunities

Youtube

₹100 cr net profit in 7-12 months | Anjali Nashier, Revolt Motors

Youtube

India's Path to Energy Security | Dr. Praveer Sinha, MD & CEO, Tata Power

  • PL Capital Logo

  • Regd. Office : 3rd Floor, Sadhana House,
    570, P. B. Marg, Behind Mahindra Tower,
    Worli, Mumbai - 400 018, India

    View on Google Maps

  • Tel. : 02266322222

    Call us

Prabhudas Lilladher Private Limited | CIN: U67190MH1983PTC029670 | Registered Office Address: 3rd Floor, Sadhana House, 570, P.B. Marg, Worli, Mumbai – 400018, Maharashtra, India | SEBI Registration Details: Stock Broking: INZ000196637 [Membership Codes: NSE – 05977; BSE – 564; MCX – 40690] | Depository Participant: IN-DP-439-2019 [DP Codes: CDSL – 12011300; NSDL – IN303868 | Portfolio Management: INP000009001| Research Analyst: INZ000000271 | Investment Advisors: INA000018267 [BSEASL Membership Code: BASL2042] | AMFI ARN: 3276 | Compliance Officer: Mrs. Snehal Kathrani; Tel: 02266322420; email: co@plindia.com | For any Grievance/ Dispute: Stock Broking; email: grievance-br@plindia.com; Tel: 02266322366; Depository Participant; email: grievance-dp@plindia.com; Tel: 02266322452; Portfolio Management; email: grievance-pms@plindia.com; Tel: 02266322350.

To register your grievance on SCORES log onto: https://scores.gov.in/scores/Welcome.html. Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, Email ID

To register your grievance on Smart ODR Portal log onto: Online Dispute Resolution Portal (ODR Portal).

Standard Disclaimers: (a) Investment in securities market are subject to market risks, read all the related documents carefully before investing. (b) Brokerage will not exceed the SEBI prescribed limits. (c) Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

The brand name and Logo ‘PL Capital’ are the registered trademarks of Prabhudas Lilladher Advisory Services Private Limited which is the holding company of Prabhudas Lilladher Group of Companies .

Prabhudas Lilladher Private Limited is not associated with any unregulated platform which claims performance/return for algorithmic strategy for trading. Trading with unregulated platforms for algorithmic strategy shall be at your own risk and Prabhudas Lilladher Private Limited or its affiliates shall not be liable for the same.

Risk Disclosure on Derivatives: (a) 9 out of 10 individual traders in equity futures and options segment, incurred net losses. (b) On an average, loss makers registered net trading loss close to ₹ 50,000 (c) Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs. (d) Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source